Morphofunctional alterations of the cardiovascular system in patients with liver cirrhosis;Alterazioni morfofunzionali del sistema cardiovascolare in pazienti con cirrosi epatica

Italian Heart Journal, Supplementi

Volumn 4, Issue 2, 2002, Pages 85-95

  Piscione, Federico ^a   Manganiello, Vincenzo ^a   Viola, Orazio ^a   Chiariello, Massimo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

ACE inhibitors; Cardiomyopathies; Hepatic disease; Nitrates; Pulmonary hypertension

Indexed keywords

BETA ADRENERGIC RECEPTOR;

BLOOD FLOW; BLOOD VOLUME; CIRCULATION; DIASTOLE; DISEASE COURSE; EXERCISE; HEART CONTRACTION; HEART DISEASE; HUMAN; LIVER CIRRHOSIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PORTAL HYPERTENSION; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; SYNDROME; VASCULAR RESISTANCE;

BLOOD CIRCULATION; BLOOD VOLUME; DIASTOLE; DISEASE PROGRESSION; EXERCISE; HEART DISEASES; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; LIVER CIRRHOSIS; MYOCARDIAL CONTRACTION; PROGNOSIS; RECEPTORS, ADRENERGIC, BETA; REGIONAL BLOOD FLOW; SYNDROME; VASCULAR RESISTANCE;

EID: 84949134917     PISSN: 15903796     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Kowalski HJ, Abelman WH. The cardiac output at rest in Laennec cirrhosis. J Clin Invest 1953; 32: 1025-33.
2. Lunseth JH, Olmstead EG, Forks G. A study of heart disease in 180 hospitalized patients dying with portal cirrhosis. Arch Intern Med 1958; 102: 405-13.
3. Ma Z, Miyamoto A, Lee S. Role of altereted β-adrenoceptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats. Gastroenterology 1996; 110: 1191-8.
4. Gerbes AL, Remien J, Jungst D, Sauerbruch T, Paumgartner B. Evidence for down-regulation of beta-2-adrenoceptors in cirrhotic patients with severe ascites. Lancet 1986; 1:1409-10.
5. Ma Z, Lee S. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 1996; 2: 451-9.
6. Dudley FJ, Murray DE. The sympathetic nervous system in cirrhosis. In: Arroyo V, Ginés P, Rodés J, Schrier W, eds. Ascites and renal dysfunction in liver disease. Oxford: Black-well Science, 1999: 198-219.
7. Fox ES, Thomas P, Broitman SA. Hepatic mechanism for clearance and detoxification of bacterial endotoxins. J Nutr Biochem 1990; 1:620-7.
8. Ma Z, Meddings JB, Lee S. Membrane physical properties determine cardiac beta-adrenergic receptors function in cirrhotic rats. Am J Physiol 1994; 267 (Part 1): G87-G93.
9. Pozzi M, Carugo S, Boari G, et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997; 26: 1131-7.
10. Finucci G, Desideri A, Sacerdoti D, et al. Left ventricular diastolic function in liver cirrhosis. Scand J Gastroenterol 1996;31:279-84.
11. Bernardi M, Rubbioli A, Trevisani F, et al. Reduced cardiovascular responsiveness to exercise-induced sympathoad-renergic stimulation in patients with cirrhosis. J Hepatol 1991; 12: 207-16.
12. Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Moller S. Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J Hepatol 2002; 36: 513-20.
13. Kelbaek H, Eriksen J, Brynjolf I, et al. Cardiac performance in patients with asymptomatic alcoholic cirrhosis of the liver. Am J Cardiol 1984; 54: 852-5.
14. Murray FJ, Dawson AM, Sherlock S. Circulatory changes in chronic liver disease. Am J Med 1958; 24: 358-67.
15. Schrier RW. Body fluid volume regulation in health and disease: a unifying hypothesis. Ann Intern Med 1990; 113: 155-9.
16. Benoit JN, Granger DN. Splanchnic hemodynamics in chronic portal hypertension. Semin Liver Dis 1986; 6: 287-98.
17. Lebrec D, Bataille C, Bercoff E, Valla D. Hemodynamic changes in patients with portal venous obstruction. Hepatology 1983; 3: 550-3.
18. Blendis LM, Banks DC, Ramboer C, Williams R. Splenic blood flow and splanchnic haemodynamics in blood dyscra-sia and other splenomegalies. Clin Sci 1970; 70: 73-84.
19. Lewis FW, Adair O, Rector WG Jr. Arterial vasodilatation is not the cause of increased cardiac output in cirrhosis. Gastroenterology 1992; 102: 1024-9.
20. Vlavianos P, Mac Mathuna P, Williams R, Westaby D. Splanchnic and systemic haemodynamic response to volume changes in patients with cirrhosis and portal hypertension. Clin Sci 1999; 96:475-81.
21. Laffi G, Barletta G, La Villa G, et al. Altered cardiovascular responsiveness to active tilting in non alcoholic cirrhosis. Gastroenterology 1997; 113: 891-8.
22. Bemardi M, Fornalè L, Di Marco C, et al. Hyperdynamic circulation of advanced cirrhosis: a re-appraisal based on posture-induced changes in hemodynamics. J Hepatol 1995; 22: 309-18.
23. Bernardi M, Di Marco C, Trevisani F, et al. The hemodynamic status of preascitic cirrhosis: an evaluation under steady-state condition and after postural change. Hepatology 1992; 16: 341-6.
24. Fernandez-Seara J, Prieto J, Qhiroga J, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without renal failure. Gastroenterology 1989; 97: 1304-12.
25. Vorobioff J, Bredfeldt JE, Groszmann RJ. Increased blood flow through the portal system in cirrhotic rats. Gastroenterology 1984; 87: 1120-6.
26. Rodriguez-Roisin R, Agusti AG, Roca J. The hepatopul-monary syndrome: new name, old complexities. Thorax 1992;47:897-902.
27. Sacerdoti D, Bolognesi M, Merkel C, Angeli P, Gatta A. Renal vasoconstriction in cirrhosis evaluated by duplex Doppler ultrasonography. Hepatology 1993; 17: 219-24.
28. Laragh JH, Cannon PJ, Bentzel CJ, et al. Angiotensin II, norepinephrine and renal transport of electrolytes and water in normal man and in cirrhosis with ascites. J Clin Invest 1963; 42: 1179-86.
29. Murray BM, Paller MS. Decreased pressor reactivity to angiotensin II in cirrhotic rats. Evidence for a post-receptor defect in angiotensin action. Circ Res 1985; 57: 424-31.
30. Hartleb M, Moreau R, Cailmail S, Gaudin C, Lebrec D. Vascular hyporesponsiveness to endothelin-1 in rats with cirrhosis. Gastroenterology 1994; 107: 1085-93.
31. Ryan J, Sudhir K, Jennings G, Esler M, Dudley F. Impaired reactivity of the peripheral vasculature to pressor agents in alcoholic cirrhosis. Gastroenterology 1993; 105: 1167-72.
32. Helmy A, Jalan R, Newby DE, Johnston NR, Hayes PC, Webb DJ. Altered peripheral vascular responses to exogenous and endogenous endothelin-1 in patients with well-compensated cirrhosis. Hepatology 2001; 33: 826-31.
33. Bruix J, Bosch J, Kravetz D, et al. Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology 1985; 88: 430-5.
34. Minok GY, McCannel KL. Is the hypotension in cirrhosis a GABA-mediated process? Hepatology 1988; 8: 73-7.
35. Villamediana LM, Sanz E, Fernandez-Gallardo S, et al. Effects of platelet-activating factor antagonist BN 52021 on the hemodynamics of rats with experimental cirrhosis of the liver. Life Sci 1986; 39: 201-5.
36. Henriksen JH, Staun-Olsen P, Borg Mogensen N, Fahrenkrug J. Circulating endogenous vasoactive intestinal polypeptide (VIP) in patients with uraemia and liver cirrhosis. Eur J Clin Invest 1986; 16:211-6.
37. Hortnagl H, Singer EA, Lenz K, Kleinberger G, Lochs H. Substance P is markedly increased in plasma of patients with hepatic coma. Lancet 1984; 2: 480-3.
38. Ohkubo H, Okuda K, Iida S, et al. Role of portal and splanchnic vein shunts and impaired hepatocyte extraction in the elevated serum bile acids in liver cirrhosis. Gastroenterology 1984; 86: 514-20.
39. Moller S, Bendsten F, Schifter S, Henricksen JH. Relation of calcitonin gene-related peptide to systemic vasodilatation and central hypovolemia in cirrhosis. Scand J Gastroenterol 1996; 31: 928-33.
40. Lòpez-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in pre-hepatic portal-hypertensive rats. Gastroenterology 1995; 108: 761-7.
41. Amai JF, Dinh-Xuan AT, Pueyo M, Darblade B, Rami J. Endothelium-derived nitric oxide and vascular physiology and pathology. Cell Mol Life Sci 1999; 55: 1078-87.
42. Battista S, Bar F, Mengozzi G, Zanon E, Grosso M, Molino G. Hyperdynamic circulation in patients with cirrhosis: direct measurement of nitric oxide levels in hepatic and portal veins. J Hepatol 1997; 26: 75-80.
43. Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993; 18: 1139-44.
44. Martin PY, Xu DL, Niederberger M, et al. Upregulation of endothelial constitutive NOS: a major role in the increased NO production in cirrhotic rats. Am J Physiol 1996; 270 (Part 2): F494-F499.
45. Wiest R, Groszmann RJ. Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin Liver Dis 1999; 19: 411-26.
46. Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstein S, Groszmann RJ. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999; 104: 1223-33.
47. Pizcueta P, Piquè JM, Fernàndez M, et al. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 1992; 103: 1909-15.
48. Niederberger M, Martin PY, Ginès P, et al. Normalization of nitric oxide production corrects arterial vasodilatation and hyperdynamic circulation in cirrhotic rats. Gastroenterology 1995; 109: 1624-30.
49. Laffi G, Foschi M, Masini E, et al. Increased production of nitric oxide by neutrophils and monocytes from cirrhotic patients with ascites and hyperdynamic circulation. Hepatology 1995; 22: 1666-73.
50. Matsumoto A, Ogura K, Hirata Y, et al. Increased nitric oxide in the exhaled air of patients with decompensated liver cirrhosis. Ann Intern Med 1995; 123: 110-3.
51. Oliver MI,Miralles R, Rubiès-Prat J, et al. Autonomic dysfunction in patients with non-alcoholic chronic liver disease. J Hepatol 1997; 26: 1242-8.
52. Coelho L, Saraiva S, Guimaraes H, Freitas D, Providencia LA. Autonomic function in chronic liver disease assessed by heart rate variability study. Rev Port Cardiol 2001; 20: 25-36.
53. Laffi G, Lagi A, Cipriani M, et al. Impaired cardiovascular autonomic response to passive tilting in cirrhosis with ascites. Hepatology 1996; 24: 1063-7.
54. Trevisani F, Sica G, Mainqua P, et al. Autonomic dysfunction and hyperdynamic circulation in cirrhosis with ascites. Hepatology 1999; 30: 1387-92.
55. Bernardi M, Calandra S, Colantoni A, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998; 27: 28-34.
56. Puthumana L, Chaudhry V, Thuluvath PJ. Prolonged QTc interval and its relationship to autonomic cardiovascular reflexes in patients with cirrhosis. J Hepatol 2001; 35: 733-8.
57. Kempler P, Szalay F, Varadi A, et al. Prolongation of the QTc-interval reflects the severity of autonomic neuropathy in primary biliary cirrhosis and in other non-alcoholic liver diseases. Z Gastroenterol 1993; 31 (Suppl 2): 96-8.
58. Finucci G, Lunardi F, Sacerdoti D, et al. Q-T interval prolongation in liver cirrhosis. Reversibility after orthotopic liver transplantation. Jpn Heart J 1998; 39: 321-9.
59. Llach J, Ginès P, Arroyo V, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to hospital for the treatment of ascites. Gastroenterology 1988; 94: 482-7.
60. Bataller R, Ginès P, Guevara M, Arroyo V. Hepatorenal syndrome. Semin Liver Dis 1997; 17: 233-47.
61. Larsen FS, Olsen KS, Ejlersen E, Hansen BA, Paulson OB, Knudsen GM. Cerebral blood flow autoregulation and trans-cranial Doppler sonography in patients with cirrhosis. Hepatology 1995; 22: 730-6.
62. Lockwood AH, Yap EWH, Wong W. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 1991; 11:337-41.
63. Moreau R, Lee SS, Soupison T. Abnormal tissue oxygenation in patients with cirrhosis and liver failure. J Hepatol 1988; 7: 98-105.
64. Waxman K, Shoemaker WC. Physiologic determinants of operative survival after portocaval shunt. Ann Surg 1983; 197: 72-8.
65. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991; 100: 520-6.
66. Schraufnagel DE, Kay JM. Structural and pathologic changes in the lung vasculature in chronic liver disease. Clin Chest Med 1996; 17: 1-7.
67. Ramsay MA, Simpson BR, Nguyen AT, Ramsay KJ, East C, Klintmalm GB. Severe pulmonary hypertension in liver transplantation candidates. Liver Transpl Surg 1997; 3:494-500.
68. Castro M, Krowka MJ, Schroeder DR, et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc 1996; 71: 543-51.
69. Lebrec D, Capron JP, Dhumeaux D, Benhamou JP. Pulmonary hypertension complicating portal hypertension. Am Rev Respir Dis 1979; 120: 849-56.
70. Nichols WC, Koller DL, Slovis B, et al. Localization of the gene for familiar primary pulmonary hypertension to chromosome 2q31-32. Nat Genet 1997; 15: 277-80.
71. Edwards BS, Weir EK, Edwards WD, Ludwig J, Dykoski RK, Edwards JE. Coexistent pulmonary and portal hypertension: morphologic and clinical features. J Am Coll Cardiol 1987; 10: 1233-8.
72. Cohen MD, Rubin U, Taylor WE, Cuthbert JA. Primary pulmonary hypertension: an unusual case associated with extrahepatic pulmonary hypertension. Hepatology 1983; 3: 588-92.
73. Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 1991; 17:492-8.
74. Koneru B, Ahmed S, Weisse AB, Grant GP, McKim KA. Resolution of pulmonary hypertension of cirrhosis after liver transplantation. Transplantation 1994; 58: 1133-5.
75. Schott R, Chaouat A, Launoy A, Pottecher T, Weitzenblum E. Improvement in pulmonary hypertension after liver transplantation. Chest 1999; 115: 1748-9.
76. Garcia-Pagan JC, Feu F, Navasa M, et al. Long-term haemodynamic effects of isosorbide-5-mononitrate in patients with cirrhosis and portal hypertension. J Hepatol 1990; 11: 189-95.
77. Bosch J, Garcia-Pagan JC, Feu F, et al. New approaches in the pharmacologic treatment of portal hypertension. J Hepatol 1993; 17 (Suppl 2): S41-S45.
78. Angelico M, Lionetti R. Long-acting nitrates in portal hypertension: to be or not to be? Dig Liver Dis 2001; 33: 205-11.
79. Lee JK, Hsieh JF, Tsai SC, Ho YJ, Kao CH. Effects of single dose of 50 mg captopril in patients with liver cirrhosis and ascites. Hepatogastroenterology 2000; 47: 767-70.
80. Van Vliet AA, Hackeng WH, Donker AJ, Meuwissen SG. Efficacy of low-dose captopril in addition to furosemide and spironolactone in patients with decompensated liver disease during blunted diuresis. J Hepatol 1992; 15: 40-7.
81. Ohnishi A, Murakami S, Harada M, et al. Renal and hormonal responses to repeated treatment with enalapril in non-azotemic cirrhosis with ascites. J Hepatol 1994; 20: 223-30.
82. Ibarra FR, Afione C, Garzon D, Barontini M, Santos JC, Arrizurieta E. Portal pressure, renal function and hormonal profile after acute and chronic captopril treatment in cirrhosis. Eur J Clin Pharmacol 1992; 43: 477-82.
83. Eriksson LS, Kagedal B, Wahren J. Effects of captopril on hepatic venous pressure and blood flow in patients with liver cirrhosis. Am J Med 1984; 31: 66-70.